Lewandowski Krzysztof C, Gąsior-Perczak Danuta, Kowalska Aldona, Lewiński Andrzej
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland.
Thyroid Res. 2012 Dec 17;5(1):20. doi: 10.1186/1756-6614-5-20.
The so called "big-big" prolactin (Prl), also known as macroprolactin is formed by Prl-immunoglobulin (Prl-IgG) complexes and may cause elevation of serum Prl concentrations measured by standard assays, potentially leading to unnecessary investigations and/or treatment. In our study, we have endeavoured to assess the prevalence of macroprolactinaemia in euthyroid, regularly menstruating women with thyroid disease, as well as to assess whether autoimmune thyroid disease may result in an increased prevalence of macroprolactinaemia.
We measured serum Prl in 182 regularly menstruating women aged 32.7 ± 7.5 years (mean ± SD, range 17-46 years) who attended endocrine clinic either for investigation of non-toxic goitre (n = 86, age 33.2 ± 7.8 years) or with autoimmune thyroid disease (n = 96, age 32.3 ± 7.2 years). Autoimmune thyroid disease was defined as raised titre of at least one anti-thyroid antibody [anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-Tg) and/or anti-TSH-receptor (anti-TSH-R) antibodies]. All women were clinically and biochemically euthyroid, either without or on treatment with L-thyroxine. In those with raised Prl (i.e., above 530 mIU/l) we ruled out the presence of macroprolactinaemia by polyethylene glycol (PEG) precipitation method.
There was no significant age difference between women with and without autoimmune thyroid disease (p = 0.84). Raised Prl concentrations were found in 10 women with thyroid disease (5.5%), and of those a significant macroprolactinaemia (i.e., reduction of Prl concentrations of more than 60% after PEG precipitation) was found in 9 subjects (4.94%). There were no differences in the prevalence of macroprolactinaemia between women with autoimmune thyroid disease (4 out of 96), and without autoimmune thyroid disease (5 out of 86, p = 0.75).
Approximately one out of twenty women with regular menses is likely to have raised serum Prl that is usually caused by the presence of macroprolactinaemia. Though structure of macroprolactin involves Prl-IgG complexes, there is no evidence that autoimmune thyroid disease is associated with raised prevalence of macroprolactinaemia.
所谓的“大大”催乳素(Prl),也称为巨催乳素,由Prl-免疫球蛋白(Prl-IgG)复合物形成,可能导致标准检测方法测得的血清Prl浓度升高,这可能会导致不必要的检查和/或治疗。在我们的研究中,我们试图评估甲状腺功能正常、月经规律的甲状腺疾病女性中巨催乳素血症的患病率,并评估自身免疫性甲状腺疾病是否可能导致巨催乳素血症患病率增加。
我们测量了182名年龄在32.7±7.5岁(平均±标准差,范围17 - 46岁)、月经规律的女性的血清Prl,这些女性因非毒性甲状腺肿(n = 86,年龄33.2±7.8岁)或自身免疫性甲状腺疾病(n = 96,年龄32.3±7.2岁)就诊于内分泌门诊。自身免疫性甲状腺疾病定义为至少一种抗甲状腺抗体[抗甲状腺过氧化物酶(抗TPO)、抗甲状腺球蛋白(抗Tg)和/或抗促甲状腺激素受体(抗TSH-R)抗体]的滴度升高。所有女性临床和生化检查均甲状腺功能正常,未接受或正在接受左甲状腺素治疗。对于Prl升高(即高于530 mIU/l)的患者,我们通过聚乙二醇(PEG)沉淀法排除巨催乳素血症的存在。
患有和未患有自身免疫性甲状腺疾病的女性之间年龄无显著差异(p = 0.84)。在10名甲状腺疾病女性中发现Prl浓度升高(5.5%),其中9名受试者(4.94%)存在显著的巨催乳素血症(即PEG沉淀后Prl浓度降低超过60%)。患有自身免疫性甲状腺疾病的女性(96名中有4名)和未患有自身免疫性甲状腺疾病的女性(86名中有5名)之间巨催乳素血症的患病率无差异(p = 0.75)。
大约每二十名月经规律的女性中就有一名可能血清Prl升高,这通常是由巨催乳素血症引起的。虽然巨催乳素的结构涉及Prl-IgG复合物,但没有证据表明自身免疫性甲状腺疾病与巨催乳素血症患病率升高有关。